Evidence map›Paper›PMID 38757319›Full record

ArticleCurrent hypertension reviews2024

Highlights from the New European Society of Hypertension Guidelines Document.

Guido Grassi

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in Current hypertension reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Guido GrassiClinica Medica, Università Milano-Bicocca, Via Pergolesi 33, 20052 Monza, Italy.ORCID 0000-0003-1922-6547

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present editorial will review the main recommendations included in the recent guidelines for the diagnosis and treatment of hypertension issued by the European Society of Hypertension. Emphasis will be given to some crucial issues of major relevance for current clinical practice, such as office and out-of-office blood pressure measurements, blood pressure threshold and targets, combination drugs, the position of beta-blocking drugs in the therapeutic intervention, and renal denervation.

Indexed as

Antihypertensive AgentsBlood PressureHypertensionPractice Guidelines as TopicAdrenergic beta-AntagonistsBlood Pressure DeterminationDrug Therapy, CombinationEuropeHumansKidneySocieties, MedicalAdrenergic beta-AntagonistsAntihypertensive Agentsantihypertensive treatmentblood pressurecardiovascular risk.clinical trialsGuidelineshypertensionrenal denervation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.